Intrahepatic Cholangiocarcinoma (Icc)NCT07760038
Protective Mechanisms of Phycocyanin in Partial Hepatectomy-Associated Liver Injury
A study testing Phycocyanin and Maltodextrin in people with Intrahepatic Cholangiocarcinoma (Icc) and Liver Injury, run by Second Affiliated Hospital, Zhejiang University, School of Medicine at 1 site in China.
Trial summary
The goal of this study is to find out whether phycocyanin, a natural protein from spirulina, can help protect the liver and support recovery in adults having part of their liver removed. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Intrahepatic Cholangiocarcinoma (Icc), Liver Injury
- What is being tested?
- Phycocyanin and Maltodextrin
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 30 participants
- Where
- 1 siteChina
- Study dates
- 1 Jun 2026to 30 May 2029
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of intrahepatic cholangiocarcinoma
- Child-Pugh class A liver function
- Planned neoadjuvant treatment with gemcitabine plus oxaliplatin, lenvatinib, and a PD-1 inhibitor
- Planned anatomical hemihepatectomy with an expected future liver remnant greater than 40%
- Age 18 to 75 years
- Willing and able to participate and provide written informed consent
- No acute illness or significant worsening of symptoms within 4 weeks before enrollment
Who cannot join
- Serious coexisting medical conditions
- Known allergy to phycocyanin
- Other malignant tumors
- Previous liver resection
- History of severe psychiatric illness that may affect treatment adherence
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
The Second Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang
Xiaopeng Cai, +86 18768161626, cxpeng@zju.edu.cn
About this study
The goal of this study is to find out whether phycocyanin, a natural protein from spirulina, can help protect the liver and support recovery in adults having part of their liver removed. The study will also look at whether phycocyanin is safe to take.The main questions are:
Does phycocyanin reduce liver injury after surgery? Does it help the liver grow back and recover? What side effects or medical problems happen while taking it?
Read more
Researchers will compare phycocyanin with a placebo, which looks similar but does not contain phycocyanin. About 30 people will take part. Each person will be randomly placed into one of the two groups, and neither the participants nor the researchers will know which treatment each person receives during the study.
Participants will:
Take 1.5 grams of phycocyanin or placebo every day for 3 weeks before surgery and 3 weeks after surgery Receive the usual care for liver surgery Give blood and stool samples before and after treatment Allow researchers to study a small piece of liver tissue removed during surgery Return for follow-up for up to 90 days after surgery
The samples will be used to check liver function, inflammation, gut bacteria, and changes linked to liver healing. Possible side effects include an allergic reaction or stomach discomfort. The study has been approved by an ethics committee.
- Being tested
- Phycocyanin, Maltodextrin
- Medical subject headings
- Cholangiocarcinoma, Cirrhosis, Familial, with Pulmonary Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PhycocyaninDietary supplement
Participants will take 1.5 grams of phycocyanin by mouth once daily for 3 weeks before partial hepatectomy and for 3 weeks after surgery. Phycocyanin is a natural protein from spirulina.
MaltodextrinDietary supplement
Participants will take 1.5 grams of maltodextrin placebo by mouth once daily for 3 weeks before partial hepatectomy and for 3 weeks after surgery. The placebo does not contain phycocyanin.
| Study group | Role | What they receive |
|---|---|---|
| Phycocyanin Group | Experimental | Participants will take 1.5 grams of phycocyanin by mouth once a day for 3 weeks before surgery and 3 weeks after surgery. They will also receive the usual medical care for partial liver removal surgery. Receives: Dietary Supplement: Phycocyanin |
| Placebo Group | Placebo comparator | Participants will take 1.5 grams of maltodextrin placebo by mouth once a day for 3 weeks before surgery and 3 weeks after surgery. The placebo does not contain phycocyanin. Participants will also receive the usual medical care for partial liver removal surgery. Receives: Dietary Supplement: Maltodextrin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Serum Aspartate Aminotransferase (AST) Level
Measured: Baseline and Week 3 after surgery
Change in Serum Alanine Aminotransferase (ALT) Level
Measured: Baseline and Week 3 after surgery
Change in Serum Total Bilirubin (TBIL) Level
Measured: Baseline and Week 3 after surgery
Secondary outcomes (3)
Change in Blood Inflammatory Marker Levels
Measured: Baseline and Week 3 after surgery
Liver Cell Proliferation Assessed by Ki-67 Expression
Measured: Baseline and Week 3 after surgery
Liver Cell Proliferation Assessed by PCNA Expression
Measured: Baseline and Week 3 after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Aug 2026
- Study start1 Jun 2026
- Primary completion30 May 2029 (estimated)
- Study completion30 May 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Intrahepatic Cholangiocarcinoma (Icc)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07760038
- Sponsor's protocol ID
- 2026-0597
- Status last verified
- Jul 2026
- First submitted
- 22 Jul 2026
- Last updated
- 12 Aug 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No